RLFTF Relief Therapeutics Holdings AG (QB)

Traders News Source Identifies Tomorrows NASDAQ’s

New York, NY – September 3, 2020 -- InvestorsHub NewsWire – Traders News Source, a leading independent equity research and corporate access firm focused on small cap growth companies issues a new research reports.

Relief Therapeutics Holdings AG (OTCPINK: RLFTF) is a Swiss-based publicly traded drug development company focusing primarily on the clinical development of peptides and proteins of natural or engineered origin to address unmet medical needs. NeuroRx, Inc. and RLFTF have announced that NeuroRx has been granted Investigational New Drug (IND) permission to test RLF-100 (aviptadil) for inhaled use in patients with moderate and severe COVID-19 in order to prevent progression to respiratory failure.

CytoDyn Inc. (OTCQB: CYDY) is a late-stage biotechnology company a late-stage biotechnology company developing leronlimab (PRO 140). On Wednesday, September 2, 2020, the company will provide a comprehensive update on the most anticipated timelines for multiple regulatory and clinical initiatives, including COVID-19 potential approval timelines in U.S. and U.K. The company has reached the requisite number of enrolled patients in its Phase 3 trial for COVID-19 patients with severe-to-critical symptoms to perform an interim analysis following the 28-day phase of the trial.

See our full report and stay engaged with the markets READ MORE
Copy and paste to browser may be required- https://tradersnewssource.com/potential-home-run-stock/

Galaxy Next Generation, Inc. (OTCQB: GAXY), a provider of interactive learning technology solutions, announced that it has completed successful installations of interactive panels at Newtown County Schools in Georgia and a school in south Florida. The interactive panels were installed under purchase orders from April 2020 of approximately $550,000 from Newton County Schools, Georgia, and a school in south Florida. The Newtown County public school district includes 20,000 students and 13 elementary schools, 5 middle schools and 3 high schools.

Northwest Biotherapeutics, Inc. (OTCQB: NWBO), is a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers. The company is pursuing an intensive program of manufacturing preparations and planning as the Company approaches top line data from its Phase III trial of DCVax®-L.  A cornerstone of this expanding program is completion of the Phase I buildout of the Sawston, UK manufacturing facility.

Our full comprehensive report is available with no obligation READ MORE
Copy and paste to browser may be required –  https://tradersnewssource.com/potential-home-run-stock/



Disclosure
 
Traders News Source LLC (TNS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE, NASDAQ, and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps.
 
TNS LLC has listed if any, all compensation in the linked full report
 
PRESS RELEASE PROCEDURES
 
The non-sponsored content contained herein has been prepared by a writer (the "Author"). Content is researched, written, and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author per the procedures outlined by TNS.
 
NO WARRANTY
 
TNS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake, or shortcoming. No liability is accepted whatsoever for any direct, indirect, or consequential loss arising from the use of this document. TNS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, TNS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
 
NOT AN OFFERING
 
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.tradersnewssource.com.
 
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer be featured on our coverage list, contact us via email at: editor@tradersnewssource.com
 

CONTACT: editor@tradersnewssource.com
SOURCE: Traders News Source

 

Relief Therapeutics (QB) (USOTC:RLFTF)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024

Relief Therapeutics (QB) (USOTC:RLFTF)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024